MAP2K2 and metastatic malignant neoplasm: Among the 49 kinases present in the Foundation One gene panel, genes in the Atypical kinase group (AKT1, AKT2, AKT3, PDK1) had the highest mutation frequently in both primary (88%) and metastatic cancers (96%), followed by genes in the STE kinase group (MAP2K1, MAP2K2, MAP2K4, MAP3K1, PAK3) which were mutated in 83% of the primary and 81% of the metastatic cancers.